Search in:

Advanced search

Expert Review of Clinical Pharmacology Volume 6, 2013 - Issue 6

Submit an article Journal homepage

Free access

1,172

Views

CrossRef citations to date

Altmetric

Drug Profile

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus

Ronnie AronsonLMC Diabetes & Endocrinology, 1929 Bayview Ave, Suite 107, Ontario, M4G 3E8, CanadaCorrespondence[email protected]

Pages 603-612 | Published online: 10 Jan 2014

Cite this article
https://doi.org/10.1586/17512433.2013.842465

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
View PDF PDF

References

Blevins T. Control of postprandial glucose levels with insulin in type 2 diabetes. Postgrad. Med. 123(4), 135–147 (2011).
PubMed Web of Science ®Google Scholar
Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32(1), 193–203 (2009).
PubMed Web of Science ®Google Scholar
Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes care 28(5), 1083–1091 (2005).
PubMed Web of Science ®Google Scholar
Raccah D, Bretzel R, Owens D, Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough - what next? Diabetes Metab. Res. Rev. 23, 257–264 (2007).
PubMed Web of Science ®Google Scholar
Riddle M, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes care 26, 3080–3086 (2003).
PubMed Web of Science ®Google Scholar
Arnolds S, Dellweg S, Clair J et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof- of-concept study. Diabetes care 33(7), 1509–1515 (2010).
PubMed Web of Science ®Google Scholar
Harris S, Kapor J, Lank C, Wilan A, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam. Physician 56(12), e418–e424 (2010).
PubMed Web of Science ®Google Scholar
Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul. Pept. 164(2–3), 58–64 (2010).
PubMedGoogle Scholar
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548), 1696–1705 (2006).
PubMed Web of Science ®Google Scholar
Visboll T, Holst J. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47(3), 357–366 (2004).
PubMed Web of Science ®Google Scholar
Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683), 39–47 (2009).
PubMed Web of Science ®Google Scholar
Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab. Vasc. Dis. Res. 9(2), 95–108 (2012).
PubMed Web of Science ®Google Scholar
Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6), 1364–1379 (2012).
PubMed Web of Science ®Google Scholar
Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J. Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 34(12), 2508–2514 (2011).
PubMed Web of Science ®Google Scholar
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8(12), 728–742 (2012).
PubMed Web of Science ®Google Scholar
Cowan J, McKay G, Fisher M. GLP-1 receptor agonists and insulin: where are we now? Pract. Diabetes 29(9), 351–352a (2012).
Google Scholar
Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372(9645), 1240–1250 (2008).
PubMed Web of Science ®Google Scholar
Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews D. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 27(6), 1335–1342 (2004).
PubMed Web of Science ®Google Scholar
Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60(5), 1561–1565 (2011).
PubMed Web of Science ®Google Scholar
Marathe C, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care 36(5), 1396–1405 (2013).
PubMed Web of Science ®Google Scholar
Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of literature. Diab. Obes. Metab. 15, 485–502 (2013).
PubMed Web of Science ®Google Scholar
UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 28). BMJ 317, 703–713 (1998).
PubMed Web of Science ®Google Scholar
Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375(9733), 2234–2243 (2010).
PubMed Web of Science ®Google Scholar
Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375(9724), 1447–1456 (2010).
PubMed Web of Science ®Google Scholar
Wang B, Zhong J, Lin H et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 15(8), 737–749 (2013).
PubMed Web of Science ®Google Scholar
Ahrén B, Leguizamo D, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care 36(9), 2543–2550 (2013).
PubMed Web of Science ®Google Scholar
Ratner RE, Hanefeld M, Shamanna P. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on sulfonylurea ± metformin (GetGoal-S). Diabetologia 54 ( Suppl. 1), S317 (2011).
Google Scholar
Riddle M, Aronson R, Home P et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal inulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36(9), 2489–2496 (2013).
PubMed Web of Science ®Google Scholar
Barnett A. Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core Evid. 6, 67–79 (2011).
PubMedGoogle Scholar
Christensen M, Knop FK, Vilsboll T, Holst JJ. Lixisenatide for type 2 diabetes mellitus. Expert Opin. Investig. Drugs 20(4), 549–557 (2011).
PubMed Web of Science ®Google Scholar
Distiller L, Ruus P. Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients. Diabetes Care 57( Suppl. 57), A154 (2008).
Google Scholar
Green BD, Flatt PR. Incretin hormone mimetics and analogues in diabetes therapeutics. Best Pract. Res. Clin. Endocrinol. Metab. 21(4), 497–516 (2007).
PubMed Web of Science ®Google Scholar
Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diab. Obes. Metab. 14(8), 675–688 (2012).
PubMed Web of Science ®Google Scholar
Horowitz M, Rayner CK, Jones KL. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes. Adv. Ther. 30(2), 81–101 (2013).
PubMed Web of Science ®Google Scholar
Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Hanefeld M. Efficacy and safety of lixisenatide once-daily versus placebo in patients with type 2 diabetes mellitus insufficiently controlled on metformin (GetGoal-F1). Diabt. Med. (2013) (In Press).
Google Scholar
Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in patients with type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diab. Obes. Metab. (2013) ( Epub ahead of print).
Google Scholar
Seino Y, Min KW, Niemoeller E, Takami A. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes. Metab. 14(10), 910–917 (2012).
PubMed Web of Science ®Google Scholar
Rosenstock JFT, Aronson R, Sauque-Reyna L, Souhami E, Ping L, Riddle M. Efficacy and safety of once-daily lixisenatide added on to titrated glargine plus oral agents in type 2 diabetes: GetGoal-Duo-1 Study. Diabetes Care. 36(9), 2497–503 (2013).
Google Scholar
Rosenstock J, Raccah D, Koranyi L. Efficacy and safety of lixisenatide once-daily versus exenatide twice-daily in patients with type 2 diabetes insufficiently controlled on metformin (GetGoal-X). Diabetologia 54 ( Suppl. 1), S317(2011).
Web of Science ®Google Scholar
Kapitza C, Forst T, Coester H, Poitiers F, Ruus P, Hincelin-Mery A. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled with metformin. Diab. Obes. Metab. 15(7), 642–649 (2013).
PubMed Web of Science ®Google Scholar
Charbonnel B, Wang E, Lin J, Davies M, Fonseca V. Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin in patients with type 2 diabetes mellitus. Presented at: American Diabetes Association 73rd Scientific Session. Chicago, IL, USA, 21–25 June(2013).
Google Scholar
Riddle M, Seino Y, Cariou B et al. Once-daily lixisenatide as add-on to basal insulin ± OADs in patients with Type 2 diabetes selectively reduces postprandial hyperglycemic daytime exposure. Presented at: American Diabetes Association 73rd Scientific Session.Chicago, IL, USA (2013).
Google Scholar
Butler P, Elashoff M, Elashoff R, Gale EAM. A critical analysis of the clinical use of incretin-based therapies. Are the GLP-1 therapies safe?. Diabetes Care 36(7), 2118–2125 (2013).
PubMed Web of Science ®Google Scholar
Buse JB, Bergenstal RM, Glass LC. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann. Int. Med. 154, 103–112 (2011).
PubMed Web of Science ®Google Scholar
Liutkus J, Rosas-Guzman J, Norwood P et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diab. Obes. Metab. 12, 1058–1065 (2010).
PubMed Web of Science ®Google Scholar
Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32(10), 1880–1860 (2009).
PubMed Web of Science ®Google Scholar
Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ. The effects of LY2198265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diab. Obes. Metab. 13(5), 418–425 (2011).
PubMed Web of Science ®Google Scholar
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 14(1), 150–156 (2011).
Google Scholar
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 26(3), 881–885 (2003).
PubMed Web of Science ®Google Scholar
Bagust A, Hopkinson PK, Maslove L, Currie CJ. The projected health burden of type 2 diabetes in the UK from 2000 to 2060. Diabet. Med. 19(s4), 1–5 (2002).
PubMedGoogle Scholar
Khardori R, Nguyen DD. Glucose control and cardiovascular outcomes: reorienting approach. Front. Endocrinol. (Lausanne.) 3, 110 (2012).
PubMedGoogle Scholar
Jendle J, Martin SA, Milicevic Z. Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opin. Investig. Drugs 21(10), 1463–1474 (2012).
PubMed Web of Science ®Google Scholar
Liu YH, Ruus P. Effect of the GLP-1 agonist AVE0010 on absorption of concomitant oral drugs. Annual Meeting American Diabetes Association, 69th Scientific Session. New Orleans, USA 2009 (Abstract 495).
Google Scholar
Ratner RE, Rosenstock J, Boka G. A dose-finding study of the new GLP-1 AVE0010 in type 2 diabetes insufficiently controlled with metformin. Annual Meeting of the American Diabetes Association: Abstract 433-P (2008).
Google Scholar
Drucker D. The biology of incretin hormones. Cell. Metab. 3, 153–165 (2006).
PubMed Web of Science ®Google Scholar

Websites

International Diabetes Federation. The Global Burden. www.idf.org/diabetesatlas/5e/the-global-burden ( Accessed 01 February 2013)
Google Scholar
Evaluate. Zealand Pharma Reports Successful Phase I/IIa Trial with ZP10 in Type 2 Diabetes Patients, 2002. www.evaluategroup.com/Universal/View.aspx?type=Story&id=199032 ( Accessed 20 June 2013)
Google Scholar
Lyxumia, INN-lixisenatide - European Medicines Agency. www.ema.europa.eu. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf
Google Scholar
FDA. Victoza (liraglutide [rDAN origin] injection) – Access data FDA. (2010). www.accessdata.fda.gov/drugsatfda_docs/label/2010/022341lbl.pdf ( Accessed 20 June 2013)
Google Scholar
Sanofi Press Release. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA. (2013). http://en.sanofi.com/Images/31904_20130219_LIXISENATIDE_en.pdf ( Accessed 20 February 2013)
Google Scholar
European Medicines Agency. Lyxumia (lixisenatide). Summary of opinion (initial authorisation). (EMA/CHMP/706420/2012). (2012). www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002445/WC500134872.pdf ( Accessed 20 June 2013)
Google Scholar
Clinicaltrials.gov. Efficacy and safety of lixisenatide versus insulin glulisine on top of insulin glargine with to without metformin in type 2 diabetic patients (GetGoal-Duo-2). www.clinicaltrials.gov/ct2/show/NCT01768559?term=12626&rank=1 ( Accessed 20 June 2013)
Google Scholar
ClinicalTrials.gov. RISE Medication Study. http://clinicaltrials.gov/ct2/show/NCT01779362?term=RISE&rank=7 ( Accessed 20 June 2013)
Google Scholar
ClinicalTrials.Gov. Evaluation of cardiovascular outcomes in patients with type 2 diabetes after acute coronary syndrome during treatment with AVE0010 (Lixisenatide) (ELIXA). http://clinicaltrials.gov/ct2/show/study/NCT01147250 ( Accessed 20 June 2013)
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus

References

Websites

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus

References

Websites

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date